Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BridgeBio Oncology Therapeutics, Inc. (BBOT)

BBOT Deprioritizes BBO-8520 in 1L NSCLC and BBO-10203 in Breast Cancer

Neutral Impact 3 of 5 other Written later

BBOT released new Phase 1 data for BBO-8520 and said it will focus its capital on BBO-8520 plus pembrolizumab in second-line-plus KRAS G12C inhibitor-experienced lung cancer and on BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers. The attached corporate presentation says BBO-8520 in first-line NSCLC and BBO-10203 in breast cancer have been deprioritized, with no near-term plans for further investment. For shareholders, the filing narrows the pipeline focus, and the company projects its $344.1 million in cash will fund operations into 2028.

Key points

  • BBO-8520 plus pembrolizumab showed a 75% objective response rate at the 500 mg once-daily dose and 53% across all dose levels (N=17) in the ONKORAS-101 study, with a June 1, 2026 data cutoff.
  • Cash, cash equivalents and marketable securities were $344.1 million as of June 30, 2026, which the company projects will fund operations into 2028.
  • BBO-11818 and BBO-10203 monotherapy data update is expected in Q4 2026; expanded BBO-8520 plus pembrolizumab data is expected in mid-2027.
  • The corporate presentation says BBO-8520 in 1L NSCLC and BBO-10203 in breast cancer have been deprioritized, with no near-term plans for further investment.

The filing

CompanyBridgeBio Oncology Therapeutics, Inc. (BBOT)
Form8-K, current report
Filed with the SECSep 8, 2026, 4:19 PM ET
Accession number0001193125-26-385225

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.